NHIC, Novartis unable to agree on Glivec price

Published: 2009-04-09 06:59:00

Updated: 2009-04-09 06:59:00

The National Health Insurance Corporation (NHIC) and Novartis Korea adjourned on April 6 two occasion of price negotiation over Glivec with no agreement on how to cope with “reasonable” price.

Now all eyes are on the Ministry for Health, Welfare and Family Affair committee's decision on the pr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK